Association of Biomarker Level with Cardiovascular Events: Results of a 4-Year Follow-Up Study.

The follow-up period was 48 months (from August-September 2014 to November 2018). The results showed that CXCL16 (p < 0.001), endocan (p < 0.001), and H-FABP (p=0.002) biomarker levels are significantly higher in outcome groups compared with those of the no-outcome group. Univariate regression analysis proved the prognostic significance of all biomarkers in cardiovascular events development. The multivariate regression analysis after the adjustment confirmed that the CXCL16 increase was associated with the "composite endpoint" (CE) development (p < 0.001) while the endocan increased due to the development of major cardiovascular events (MACE) (p=0.008); we did not find the association of the risks of event development with the H-FABP level increase (p=0.83).